Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Arct-032
Cystic Fibrosis, Cftr Gene Mutation
Phase II
Recruiting
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Dec 17, 2024
―
Arct-2304, Control Vaccine Younger Adults, Control Vaccine Older Adults
Influenza, Human
Phase I
Active Not Recruiting
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
Sep 16, 2024
―
Arct-810
Otc Deficiency, Ornithine Transcarbamylase Deficiency, Otcd
Phase II
Recruiting
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Jun 28, 2024
―
Influenza Vaccine, Arct-2303, Influenza Vaccine, Adjuvanted
Covid-19
Phase III
Completed
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Feb 23, 2024
―
Arct-2138, Licensed Quadrivalent Vaccine For Younger Adults, Licensed Quadrivalent Vaccine For Older Adults
Influenza, Human
Phase I
Completed
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
Nov 05, 2023
―
Arct-032
Cystic Fibrosis
Phase I
Completed
Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
Jan 26, 2023
―
Arct-810
Otc Deficiency, Ornithine Transcarbamylase Deficiency, Otcd
Phase II
Terminated
Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
Aug 08, 2022
―
Arct-021, Arct-165, Arct-154
Covid-19, Sars-Cov-2 Infection, Corona Virus Infection
Phase I/II
Completed
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
Aug 30, 2021
―
Arct-021
Sars-Cov-2
Phase II
Terminated
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Jan 24, 2021
―
Arct-021 Single Dose Priming, Arct-021 Two Lower Dose Priming, Arct-021 Two Higher Dose Priming, Randomized Booster
COVID19, Sars-Cov Infection, Corona Virus Infection
Phase II
Terminated
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
Nov 25, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Arcturus Therapeutics (ARCT) have in its pipeline
ARCT is currently developing the following drugs: Arct-032, Arct-2304, Control Vaccine Younger Adults, Control Vaccine Older Adults, Arct-810. These drug candidates are in various stages of clinical development as the company works toward FDA approval.